Merck will miss long-promised target for filing Ebola vaccine license with FDA

The world is going to have to wait a little longer for the Merck Ebola vaccine.

Though Merck had repeatedly said it would file its licensure application with the Food and Drug Administration by the end of 2017, the company will not meet that self-imposed target, the team leader for the Ebola vaccine project told STAT on Friday.

“We have faced a number of challenges that have led to some delays. So we are not going to be able to make our December 2017 filing target that was frankly developed a number of years ago,” Beth-Ann Coller said in an interview.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In